Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Biogen and Sage Therapeutics' zuranolone has become the first oral drug to be approved by the FDA for post-partum depression (PPD), but the US regulator turned down a request for wider use in the ...

Since then, Sage has weathered numerous pipeline setbacks, but zuranolone has secured FDA approval to treat PPD. Despite that approval, the FDA simultaneously rejected the drug in major depressive ...

Back in November 2020, Sage and Biogen teamed up to develop and commercialize zuranolone in major depressive disorder (MDD), postpartum depression (PPD) another other psychiatric disorders ...